Friday, February 27, 2026

Evinova integrates Citeline data into AI-native Study Designer

Evinova and Citeline have signed a multi-year agreement to integrate data from Citeline’s Sitetrove and Trialtrove databases into Evinova’s AI-native Study Designer. The collaboration was announced on 26 February 2026.

The integration is intended to support more data-driven decision-making during clinical trial design. Customers with access to Sitetrove and Trialtrove will be able to use investigator information and cross-industry trial benchmarks directly within Study Designer.

What data is being added

• Sitetrove: A database covering more than 500,000 investigators and 190,000 trial sites across 185 countries.
• Trialtrove: Curated intelligence sourced from more than 60,000 inputs, including trial design elements, enrollment timelines, patient populations, endpoints, outcomes, and geographic trends.

Why it matters for study planning

Both companies highlight that study design choices can influence cost, feasibility, site workload, patient experience, and other operational factors. By bringing external trial intelligence into the planning workflow, the partners aim to help teams compare options faster and optimize design decisions earlier.

Product and company context

Evinova positions Study Designer as part of a broader AI-native clinical development platform and states the product is built on a USDM 4.0 foundation. Citeline, a Norstella company, provides clinical and regulatory intelligence products for life science organizations.